Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-Positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy

Trial Profile

An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-Positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Fluorouracil
  • Indications Inflammatory breast cancer
  • Focus Therapeutic Use
  • Acronyms BEVERLY2
  • Sponsors Roche
  • Most Recent Events

    • 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Aug 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2014 to 1 Oct 2014.
    • 14 Dec 2013 Three-year results presented at the 36th Annual San Antonio Breast Cancer Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top